Proximity-induced protein degradation using targeted degraders has emerged recently as a favorable approach in drug discovery and development. In one of the approaches, E3 ligases are being reprogrammed by monovalent small molecules, referred to as molecular glues. Ligand binding to the E3 ligase modifies protein interface properties, leading to dimerization with a neosubstrate. It has become clear lately that molecular glue type of binding can be considered as a new modality option, specifically for otherwise poorly druggable protein targets. This way, inducing protein degradation via small molecules has become a favorable therapeutic paradigm.